Last updated
Europe Biosimilar Market Outlook
Base Year: 2024
Historical Years: 2019-2024
Forecast Years: 2025-2033
Market Size in 2024: USD 13,864 Million
Market Forecast in 2033: USD 59,733.3 Million
Market Growth Rate: 17.1% (2025-2033)
The Europe biosimilar market was valued at USD 13,864 Million in 2024 and is projected to grow to USD 59,733.3 Million by 2033, with an expected compound annual growth rate (CAGR) of 17.1% from 2025 to 2033.
Europe Biosimilar Market Trends:
The European market is largely driven by the surging need for affordable treatment alternatives, especially among those suffering from chronic diseases. In addition, the increas the biologic drugs' conclusion of patent exclusivity will enable more biosimilars to land to market, driving market expansion. At the same time, the rising healthcare infrastructure across the region will facilitate and accept the introduction of biosimilars into practice with supportive regulatory practices. Furthermore, the growing expenditure on the healthcare system in Europe allows patients and providers the potential to decide on biosimilars as an alternative.
The growing emphasis on a downwards trend in costs of healthcare has also advanced the acceptance and use of biosimilars since they have a potential for still reduced costs while maintaining efficacy and functionality for the treatment of patients and pfleges the continual growth of the market. In addition, the growing support from government and health organizations will increase biosimilar growth in the market. Along with, the growing awareness campaigns that highlight the safety and efficacy of using biosimilars will enhance acceptance from providers and patients. In addition, pharmaceutical companies investment in biosimilar research and development provides more market potential and allow for innovation and competition.
Europe Biosimilar Market Scope and Growth Analysis:
The market is experiencing a significant expansion, driven by increased therapeutic applications in oncology, immunology, and endocrinology, which are supporting unmet clinical needs. In addition, the increased use of biosimilars in hospitals will help facilitate their acceptance as a mainstream therapeutic option, providing a stronger market position. Furthermore, the increasing availability of low-cost biosimilar drugs is providing equal access to new therapies, especially in developing economies in Europe. Moreover, the strong partnership between regulatory agencies and pharmaceutical firms is enabling an accelerated approval process for biosimilars, leading to an expedited product launch.
The increasing number of local producers is diversifying the market to meet regional needs or preferences. Additionally, the new manufacturing technologies are driving production efficiency, reducing costs, and impacting the supply chain. The heightened focus on biosimilar interchangeability is also increasing provider confidence and market acceptance. Market reports describe that changing reimbursement policies that support biosimilar adoption, are a significant contributor to the market outlook; creating a more favorable environment for both industry players and healthcare systems.
By the IMARC Group, the Top Competitive Landscapes Operating in the Industry:
Novartis
Pfizer
Teva
Celltrion
Merck Sharp & Dohme
Samsung Bioepis
Eli Lilly
Accord Healthcare Ltd.
Amgen
Boehringer Ingelheim
Hexal Ag
Apotex
Stada Arzneimittel Ag
Ratiopharm
Mylan
The market report offers a comprehensive analysis of the segments, highlighting those with the largest Europe biosimilar market share. It includes forecasts for the period 2025-2033 and historical data from 2019-2024 for the following segments.
Breakup by Molecule:
Infliximab
Insulin Glargine
Epoetin Alfa
Etanercept
Filgrastim
Somatropin
Rituximab
Follitropin Alfa
Adalimumab
Breakup by Indication:
Auto-Immune Diseases
Blood Disorder
Diabetes
Oncology
Growth Deficiency
Female Infertility
Breakup by Manufacturing Type:
In-house Manufacturing
Contract Manufacturing
Breakup by Country:
Italy
Germany
United Kingdom
France
Spain
Rest of Europe
Key highlights of the Report:
Market Performance (2019-2024)
Market Outlook (2025-2033)
COVID-19 Impact on the Market
Porter’s Five Forces Analysis
Strategic Recommendations
Historical, Current and Future Market Trends
Market Drivers and Success Factors
SWOT Analysis
Structure of the Market
Value Chain Analysis
Comprehensive Mapping of the Competitive Landscape
Note: If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.
About Us:
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services.
IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145
For an in-depth analysis, you can refer free sample copy of the report:
Ask Analyst For Customization:
and Segmentation:
